MA-0204 is a highly selective and orally available peroxisome proliferator-activated receptor δ (PPARδ) modulator (EC50s: 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively). It is a potential treatment for Duchene Muscular Dystrophy (DMD).

PPARδ:10 nM (EC50)(in rat), PPARδ:0.4 nM (EC50)(in human), PPARδ:7.9 nM (EC50)(in mouse)

MA-0204 is >10,000-fold selective for activating PPARδ over PPARα and PPARγ receptors. At concentrations of 1.2-12 nM, MA-0204 enhances fatty acid oxidation in muscle myoblasts from DMD patients in mice, shows high protein binding in mouse plasma, exhibits good permeability, and has low potential for efflux. [C.]

In the muscle, PPARδ (30, 100 mg/kg) enhances target gene transcription.